Enlicitide chloride

Enlicitide chloride
Identifiers
	IUPAC name [6-[[(11S,17S,20S,23S,27S,39S,42S,63S,66R)-47-fluoro-20-[(1R)-1-hydroxyethyl]-17-[(4-methoxyphenyl)methyl]-11,63-dimethyl-10,16,19,22,30,40,58,61,64,67,70-undecaoxo-28-oxa-1,9,15,18,21,24,31,41,51,62,65,68-dodecazanonacyclo[37.18.11.23,6.124,42.133,37.144,51.011,15.023,27.045,50]triheptaconta-3(73),4,6(72),33,35,37(71),44(69),45(50),46,48-decaen-66-yl]methylamino]-6-oxohexyl]-trimethylazanium chloride;
CAS Number	2407527-16-4;
PubChem CID	166642685;
UNII	3D2DNA8NXK;
Chemical and physical data
Formula	C82H110ClFN14O15
Molar mass	1586.31 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1C(=O)NC(C(=O)NC2CC3=CC(=CC=C3)CNC(=O)COC4CCN5C4C(=O)NC(C(=O)NC(C(=O)N6CCCC6(C(=O)NCCC7=CC=C(CN(CCCCCCN8C=C(CC(C5=O)NC2=O)C9=C8C=CC(=C9)F)C(=O)CCC(=O)N1)C=C7)C)CC1=CC=C(C=C1)OC)C(C)O)CNC(=O)CCCCC[N+](C)(C)C.[Cl-];
	InChI InChI=InChI=1S/C82H109FN14O15.ClH/c1-51-74(103)91-65(47-86-68(99)19-11-10-14-40-97(4,5)6)76(105)88-62-43-56-17-15-18-57(41-56)46-85-70(101)50-112-67-33-39-95-73(67)78(107)92-72(52(2)98)77(106)90-63(42-54-24-27-60(111-7)28-25-54)80(109)96-38-16-34-82(96,3)81(110)84-35-32-53-20-22-55(23-21-53)48-94(71(102)31-30-69(100)87-51)37-13-9-8-12-36-93-49-58(44-64(79(95)108)89-75(62)104)61-45-59(83)26-29-66(61)93;/h15,17-18,20-29,41,45,49,51-52,62-65,67,72-73,98H,8-14,16,19,30-40,42-44,46-48,50H2,1-7H3,(H8-,84,85,86,87,88,89,90,91,92,99,100,101,103,104,105,106,107,110);1H/t51-,52+,62-,63-,64-,65+,67-,72-,73-,82-;/m0./s1; Key:CLOLWQCFULXMAR-QQCDJELVSA-N;

Enlicitide chloride (INN;^[1] previously known as MK-0616) is a macrocyclic peptide investigational drug who is being evaluated for the treatment of hypercholesterolaemia. It is a PCSK9 inhibitor.^[2]

Merck has launched a Phase 3 clinical trial to evaluate the efficacy and safety of MK-0616 in Adults With Hypercholesterolemia. ^[3]^[4]

References

^ "Recommended International Nonproprietary Names: List 90" (PDF). WHO Drug Information. 37 (3): 753–754. ISBN 978-92-4-008139-0.
^ Burnett JR, Hooper AJ (2023). "MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment". Expert Opinion on Investigational Drugs. 32 (10): 873–878. doi:10.1080/13543784.2023.2267972. PMID 37815341. S2CID 263802012.
^ "A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids". ClinicalTrials.gov. 2024-05-17.
^ "The MK-0616 Information Center". MK-0616.com. 2024-07-07.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.